Plus   Neg

Stock Alert: Aclaris Therapeutics Up 40%

Shares of Aclaris Therapeutics, Inc. (ACRS) are currently gaining nearly 40% on Monday morning despite no stock-specific news. Pharma companies are performing better on Monday as investors are more interested in the industry on the back of positive reports of COVID-19 vaccine.

ACRS is currently trading at $3.08, up $0.87 or 39.37%, on the Nasdaq.

Aclaris Therapeutics is a biopharmaceutical company focused on developing drug candidates for immuno-inflammatory diseases in the US. It operates in two segments, Therapeutics and Contract Research.

Meanwhile, a coronavirus vaccine the University of Oxford is developing with AstraZeneca demonstrated promising results in early human testing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT